B. Uhlig‐Laske

Statistics

Publications

Citations

185

H-Index

Active since

2010

Affiliations

Boehringer Ingelheim (Germany)(Current)

Institut für Klinische Forschung und Entwicklung

B. Uhlig‐Laske is an author at Boehringer Ingelheim (Germany) specializing in diabetes mellitus, diabetes management, and oral antidiabetic medications.

Publications per year

2010–2011

Publications

Linagliptin (BI 1356), a potent and selective DPP‐4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

Thomas Först, B. Uhlig‐Laske, Arne Ring et al. · Diabetic Medicine · 2010 · 130 citations

Medicine, Pharmacology, Pharmacotherapy +17

The oral DPP‐4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus

Thomas Först, B. Uhlig‐Laske, Arne Ring et al. · Diabetes Obesity and Metabolism · 2011 · 55 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

1–2 of 2